ASH 2014 – Castleman's Disease

Adding Rituximab to CHOP Improves Clinical Outcomes in Mantle-Cell Lymphoma

ASH 2014 – Castleman's Disease

Ibrutinib Monotherapy in Patients with Relapsed/Refractory Follicular Lymphoma

ASH 2014 – Castleman's Disease

Safety and Efficacy of Ibrutinib plus Rituximab in Relapsed Mantle-Cell Lymphoma

ASH 2014 – Castleman's Disease

Combination of Ibrutinib and BCL-2 or Spleen Tyrosine Kinase Inhibitors in Ibrutinib-Resistant Diffuse Large B-Cell Lymphoma

ASH 2014 – Castleman's Disease

Ibrutinib in Patients with Bortezomib-Refractory Mantle-Cell Lymphoma

ASH 2014 – Castleman's Disease

Ibrutinib in Relapsed/Refractory Mantle-Cell Lymphoma: 2-Year Results of Safety and Durability of Response

ASH 2014 – Castleman's Disease

The Role of Hepcidin in Multicentric Castleman Disease

ASH 2014 – Castleman's Disease

Idiopathic Castleman Disease: Clinical Features and Therapeutic Options

ASH 2014 – Castleman's Disease

Restoration of Health with Siltuximab in Multicentric Castleman Disease

ASH 2014 – Castleman's Disease

Siltuximab Efficacy in Multicentric Castleman’s Disease Is Independent of Baseline Symptom Burden

ASH 2014 – Castleman's Disease

Page 1 of 2

1
2